(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 4 July 2002 (04.07.2002)

PCT

(10) International Publication Number WO 02/051986 A3

(51) International Patent Classification7:

A61K 38/19

(21) International Application-Number: PCT/IL01/01197

(22) International Filing Date:

ate:
24 December 2001 (24.12.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

140537


25 December 2000 (25.12.2000) Π.

(71) Applicant (for all designated States except US): HAD-ASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. [IL/IL]; P.O. Box 12000, 91120 Jerusalem (IL).

- (72) Inventor; and
- (75) Inventor/Applicant (for US only): ILAN, Yaron [IL/IL]; 4/5 Yehoshua Bitzur Street, 96347 Jerusalem (IL).
- (74) Agents: LUZZATTO, Kfir et al.; Luzzatto & Luzzatto, P.O. Box 5352, 84152 Beer-Sheva (IL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: EDUCATED NK T CELLS AND THEIR USES IN THE TREATMENT OF IMMUNE-RELATED DISORDERS



(57) Abstract: The present invention relates to a method for the treatment of immune-related disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NK T cell population in said subject by suitable means, said manipulation of the NK T cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NK T cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NK T cells, such that the educated NK T cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NK T cell. The invention further provides for an ex vivo educated NK T cell and uses thereof in the treatment of immune-related disorders.



European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 12 September 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

intel nal Application No PCT/IL 01/01197

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, CHEM ABS Data, SCISEARCH

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
	TROP S ET AL: "LIVER-ASSOCIATED LYMPHOCYTES EXPRESSING NK1.1 ARE ESSENTIAL FOR ORAL IMMUNE TOLERANCE INDUCTION IN A MURINE MODEL" HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 29, no. 3, March 1999 (1999-03), pages 746-755, XP000990485 ISSN: 0270-9139 abstract; figures 2,5; table 1 -/	1-55	
X Furt	er documents are listed in the continuation of box C. X Patent family members	are listed in annex.	

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.		
 Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 	 *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family 		
Date of the actual completion of the international search	Date of mailing of the international search report		
22 May 2002	24/06/2002		
Name and mailing address of the ISA	Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Novak, S		

Intel Inal Application No
PCT/IL 01/01197

		PC1/1L 01/0119/		
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	ILAN YARON ET AL: "Treatment of experimental colitis by oral tolerance induction: A central role for suppressor lymphocytes." AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 95, no. 4, April 2000 (2000-04), pages 966-973, XP002199588 ISSN: 0002-9270 abstract; figures 1,2,4,7	1-55		
X	BURDIN N ET AL: "IMMUNOZATION WITH ALPHA-GALACTOSYLCERAMIDE POLARIZES CD1-REACTIVE NK T CELLS TOWARDS TH2 CYTOKINE SYNTHESIS" EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 29, 1999, pages 2014-2025, XP002938932 ISSN: 0014-2980 abstract; figures 1-3,5,6	1-55		
Y	SREDNI BENJAMIN ET AL: "Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101." JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 88, no. 18, 1996, pages 1276-1284, XP002196802 ISSN: 0027-8874 the whole document	1-55		
Y	US 5 721 351 A (LEVINSON DOUGLAS ADAM) 24 February 1998 (1998-02-24) the whole document	1-55		
Y .	US 6 066 498 A (LEVINSON DOUGLAS ADAM) 23 May 2000 (2000-05-23) page 36, column 1 -page 70, column 70	1-55		
Y	GOTSMAN I ET AL: "Effect of peripheral immune tolerance on liver-associated lymphocytes expressing NK1.1." TRANSPLANTATION PROCEEDINGS, vol. 32, no. 4, June 2000 (2000-06), pages	1-55		
.*	749-750, XP002199589 Fifth Annual Congress of the Transplantation Society of Israel; Nazareth, Israel; June 02-05, 1999 ISSN: 0041-1345 the whole document	·		
A	US 6 066 322 A (LEVINSON DOUGLAS ADAM) 23 May 2000 (2000-05-23)			
	-/	·		

Inter 121 Application No
PCT/IL 01/01197

	ion) DOCUMENTS CONSIDERED TO BE RELEVANT	In.
ategory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	SHLOMAI AMIR ET AL: "Immunomodulation of experimental colitis: The role of NKI. I liver lymphocytes and surrogate antigens: Bystander effect." JOURNAL OF PATHOLOGY, vol. 195, no. 4, November 2001 (2001-11), pages 498-507, XP002196803 ISSN: 0022-3417	
İ		
	*	
'		
	•	
		*
)	
-		
	·	
	· · · · · · · · · · · · · · · · · · ·	
-		

Intel 1al Application No PCT/IL 01/01197

· · · · · · · · · · · · · · · · · · ·		101/12 01/0113/			
Patent document cited in search report		Publication date	_	Patent family member(s)	Publication date
US 5721351	Α	24-02-1998	US	6066322 A	23-05-2000
		_,	AU	718245 B2	13-04-2000
			AU	5178396 A	23-09-1996
			CA	2214589 A1	12-09-1996
			EP	0813538 A1	29-12-1997
			JP	11501807 T	16-02-1999
			WO	9627603 A1	12-09-1996
			ÜS	6066498 A	23-05-2000
			US	6204371 B1	20-03-2001
			US	6084083 A	04-07-2000
			US	6288218 B1	11-09-2001
			US	6156887 A	05-12-2000
US 6066498	Α	23-05-2000	US	5721351 A	24-02-1998
			US	6066322 A	23-05-2000
			AU	718245 B2	13-04-2000
			AU	5178396 A	23-09-1996
			CA	2214589 A1	12-09-1996
			EP	0813538 A1	29-12-1997
			JP	11501807 T	16-02-1999
•			WO	9627603 A1	12-09-1996
			U\$	6204371 B1	20-03-2001
			US	6084083 A	04-07-2000
			US ,	6288218 B1	11-09-2001
			US	6156887 A	05-12-2000
US 6066322	Α	23-05-2000	AU	718245 B2	13-04-2000
			AU	5178396 A	23-09-1996
			CA	2214589 A1	12-09-1996
			EP	0813538 A1	29-12-1997
			JP	11501807 T	16-02-1999
			MO	9627603 A1	12-09-1996
			US	6066498 A	23-05-2000
			US	5721351 A	24-02-1998
			US	6204371 B1	20-03-2001
			US	6084083 A	04-07-2000
			US	6288218 B1	11-09-2001
			US	6156887 A	05-12-2000